Pancreatic Cancer Research

ResearcherCity of HopeActive in the last 2 years

Thinzar Min Lwin

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-1820-088X; OpenAlex author ID A5030393864. Sources: OpenAlex.

Their work

Papers
14
Trials
0
Grants
0
Labs led
0
Collaborators
20
Papers, trials and grants by year

2017: 2 papers · 2018: 5 papers · 2019: none · 2020: 2 papers · 2021: none · 2022: 2 papers · 2023: 1 paper · 2024: 1 paper · 2025: 1 paper

Papers 14

  1. Brightly Visualizing Pancreatic Cancer Margins in Orthotopic Mouse Models with an Anti-CA19-9 Antibody Conjugated to a Near-Infrared Fluorophore. Co-author DOI 10.3390/cancers17162617↗
  2. Targeting Human Pancreatic Cancer with a Fluorophore-Conjugated Mucin 4 (MUC4) Antibody: Initial Characterization in Orthotopic Cell Line Mouse Models. Co-author DOI 10.3390/jcm13206211↗
  3. Proof of Principle of Combining Fluorescence-Guided Surgery with Photoimmunotherapy to Improve the Outcome of Pancreatic Cancer Therapy in an Orthotopic Mouse … Co-author DOI 10.1245/s10434-022-12466-4↗
  4. Fluorescent Anti-MUC5AC Brightly Targets Pancreatic Cancer in a Patient-derived Orthotopic Xenograft. Co-author DOI 10.21873/invivo.12676↗
  5. Fluorescent Anti-CEA Nanobody for Rapid Tumor-Targeting and Imaging in Mouse Models of Pancreatic Cancer. Co-author DOI 10.3390/biom12050711↗
  6. Tumor-specific near-infrared nanobody probe rapidly labels tumors in an orthotopic mouse model of pancreatic cancer. Co-author DOI 10.1016/j.surg.2020.02.020↗
  7. The future of tumour-specific fluorescence-guided surgery for pancreatic cancer. Co-author DOI 10.1016/s2468-1253(20)30123-0↗
  8. MEK inhibitor trametinib in combination with gemcitabine regresses a patient-derived orthotopic xenograft (PDOX) pancreatic cancer nude mouse model. Co-author DOI 10.1016/j.tice.2018.05.003↗
  9. The development of fluorescence guided surgery for pancreatic cancer: from bench to clinic. Co-author DOI 10.1080/14737140.2018.1477593↗
  10. Targeting altered cancer methionine metabolism with recombinant methioninase (rMETase) overcomes partial gemcitabine-resistance and regresses a patient-derived… Co-author DOI 10.1080/15384101.2018.1445907↗
  11. Tumor-Specific Labeling of Pancreatic Cancer Using a Humanized Anti-CEA Antibody Conjugated to a Near-Infrared Fluorophore. Co-author DOI 10.1245/s10434-018-6344-6↗
  12. Fluorescent humanized anti-CEA antibody specifically labels metastatic pancreatic cancer in a patient-derived orthotopic xenograft (PDOX) mouse model. Co-author DOI 10.18632/oncotarget.26484↗
  13. Color-coded intravital imaging demonstrates a transforming growth factor-β (TGF-β) antagonist selectively targets stromal cells in a human pancreatic-cancer or… Co-author DOI 10.1080/15384101.2017.1315489↗
  14. MEK inhibitors cobimetinib and trametinib, regressed a gemcitabine-resistant pancreatic-cancer patient-derived orthotopic xenograft (PDOX). Co-author DOI 10.18632/oncotarget.17667↗

Closest collaborators

The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Michael Bouvet · 14 shared papers, 2017–2025 · strength 1.77
  2. Robert M. Hoffman · 14 shared papers, 2017–2025 · strength 1.77
  3. Surinder K. Batra · 3 shared papers, 2022–2025 · strength 0.53
  4. Kavita B. Mallya · 3 shared papers, 2022–2025 · strength 0.53
  5. Michael A. Turner · 3 shared papers, 2022–2023 · strength 0.51
  6. Hiroto Nishino · 3 shared papers, 2022–2023 · strength 0.51
  7. Sunidhi Jaiswal · 2 shared papers, 2024–2025 · strength 0.39
  8. Kristin E. Cox · 2 shared papers, 2024–2025 · strength 0.39
  9. Maneesh Jain · 2 shared papers, 2024–2025 · strength 0.39
  10. Aaron M. Mohs · 2 shared papers, 2024–2025 · strength 0.39
  11. Kentaro Miyake · 5 shared papers, 2017–2018 · strength 0.36
  12. Takashi Murakami · 5 shared papers, 2017–2018 · strength 0.35
  13. Kei Kawaguchi · 3 shared papers, 2017–2018 · strength 0.20
  14. Michiaki Unno · 3 shared papers, 2017–2018 · strength 0.20
  15. Ho Kyoung Hwang · 3 shared papers, 2017–2018 · strength 0.19
  16. Andrew M. Lowy · 1 shared paper, 2022 · strength 0.14
  17. Sukhwinder Kaur · 1 shared paper, 2022 · strength 0.14
  18. Yasushi Ichikawa · 1 shared paper, 2017 · strength 0.06
  19. Yukihiko Hiroshima · 1 shared paper, 2017 · strength 0.06
  20. Itaru Endo · 1 shared paper, 2017 · strength 0.06

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.